Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...
Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
GlobalData on MSN14d
FDA approves Amgen’s combo therapy for colorectal cancerAmgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.
Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...
The FDA has given accelerated approval to Krazati (adagrasib) as a combination with Eli Lilly’s anti-EGFR-antibody Erbitux (cetuximab) to treat patients with KRAS G12C-mutated, locally advanced ...
At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...
KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback